Serotonergic involvement in methamphetamine-induced locomotor activity: A detailed pharmacological study

Behavioural Brain Research

Volumn 220, Issue 1, 2011, Pages 9-19

  Steed, Emily ^a,b   Jones, Caitlin A ^a,c   McCreary, Andrew C ^a  

^a Chemical Design and Synthesis Unit   (Netherlands)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

5 HT1B; 5 HT2A; 5 HT2C; D1; D2; Dopamine receptors; Methamphetamine; Serotonin receptors

Indexed keywords

1,2,3,4,8,9,10,10A OCTAHYDRO 7BH CYCLOPENTA[B][1,4]DIAZEPINO[6,7,1 HI]INDOLE; 2 (6 CHLORO 5 FLUORO 1 INDOLYL) 1 METHYLETHYLAMINE; 6 CHLORO 5 METHYL 1 [[2 [(2 METHYL 3 PYRIDYL)OXY] 5 PYRIDYL]CARBAMOYL]INDOLINE; 8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; ARIPIPRAZOLE; CLOZAPINE; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; FENCLONINE; FLUVOXAMINE; HALOPERIDOL; METHAMPHETAMINE; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; N [4 METHOXY 3 (4 METHYL 1 PIPERAZINYL)PHENYL] 2' METHYL 4' (5 METHYL 1,2,4 OXADIAZOL 3 YL)[1,1' BIPHENYL] 4 CARBOXAMIDE; SEROTONIN 1A RECEPTOR; SEROTONIN 1B RECEPTOR; SEROTONIN 2A RECEPTOR; SEROTONIN 2C RECEPTOR; TERGURIDE; VOLINANSERIN;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DOPAMINERGIC SYSTEM; HYPERACTIVITY; LOCOMOTION; MALE; NERVE STIMULATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; RAT; SEROTONINERGIC SYSTEM;

ANALYSIS OF VARIANCE; ANIMALS; BRAIN; CENTRAL NERVOUS SYSTEM STIMULANTS; DOPAMINE; DOPAMINE AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; MALE; METHAMPHETAMINE; MOTOR ACTIVITY; RATS; RATS, WISTAR; SEROTONIN; SEROTONIN AGENTS;

EID: 79751530808     PISSN: 01664328     EISSN: 18727549     Source Type: Journal    
DOI: 10.1016/j.bbr.2011.01.026     Document Type: Article

References (85)

1. Anglin M.D., Burke C., Perrochet B., Stamper E., Dawud-Noursi S. History of the methamphetamine problem. J Psychoactive Drugs 2000, 32:137-141.
2. Kamei H, Nagai T., Nakano H., Togan Y., Takayanagi M., Takahashi K., et al. Repeated methamphetamine treatment impairs recognition memory through a failure of novelty-induced ERK1/2 activation in the prefrontal cortex of mice. Biol Psychiatry 2006, 59:75-84.
3. Volkow N.D., Chang L., Wang G.J., Fowler J.S., Franceschi D., Sedler M.J., et al. Association of dopamine transporter reduction with psychomotor impairment in methamphetamine abusers. Am J Psychiatry 2001, 158:377-382.
4. Bennett B.A., Hollingsworth C.K., Martin S., Harp J.J. Methamphetamine-induced alterations in dopamine transporter function. Brain Res 1997, 782:219-227.
5. Kokoshka J.M., Metzger R.R., Wilkins D.G., Gibb J.W., Hanson G.R., Fleckenstein A.E. Methamphetamine treatment rapidly inhibits serotonin, but not glutamate, transporters in the rat brain. Brain Res 1998, 799:78-83.
6. Fleckenstein A.E., Haughey H.M., Metzger R.R., Kokoshka J.M., Riddle E.L., Hanson J.E., et al. Differential effects of psychostimulants and related agents on dopaminergic and serotonergic transporter function. Eur J Pharmacol 1999, 382:45-49.
7. Fleckenstein A.E., Gibb J.W., Hanson G.R. Differential effects of stimulants on monoaminergic transporters: pharmacological consequences and implications for neurotoxicity. Eur J Pharmacol 2000, 406:1-13.
8. Borycz J., Zapata A., Quiroz C., Volkow N.D., Ferre S. 5-HT1B receptor-mediated serotonergic modulation of methylphenidate locomotor activation in rats. Neuropsychopharmacology 2008, 33:619-626.
9. Kuczenski R., Segal D.S., Cho A.K., Melega W. Hippocampus norepinephrine, caudate dopamine and serotoning, and behavioural response to the stereoisomers of amphetamine and methamphetamine. J Neurosci 1995, 15:1308-1317.
10. Sonsalla P.K., Gibb J.W., Hanson G.R. Roles of D1 and D2 dopamine receptor sub types in mediating the methamphetamine-induced changes in monoamine systems. J Pharmacol Exp Ther 1986, 238:932-937.
11. French D., Witkin J.M. Effects of the dopamine release inhibitor, CGS 10746B, on the locomotor stimulant and discriminative stimulus effects of cocaine and methamphetamine. Pharmacol Biochem Behav 1993, 46:989-993.
12. Witkin J.M., Savtchenko N., Mashkovsky M., Beekman M., Munzar P., Gasior M., et al. Behavioural, toxic, and neurochemical effects of sydnocarb, a novel psychomotor stimulant: comparisons with methamphetamine. J Pharmacol Exp Ther 1999, 288:1298-1310.
13. Kelly M.A., Low M.J., Rubinstein M., Phillips T.J. Role of dopamine D1-like receptors in methamphetamine locomotor responses of D2 receptor knockout mice. Genes Brain Behav 2008, 7:568-577.
14. Shuto T., Kuroiwa M., Hamamura M., Yabuuchi K., Shimazoe T., Watanabe S., et al. Reversal of methamphetamine-induced behavioural sensitization by repeated administration of a dopamine D1 receptor agonist. Neuropharmacology 2006, 50:991-997.
15. Hall D.A., Powers J.P., Gulley J.M. Blockade of D1 dopamine receptors in the medial prefrontal cortex attenuates amphetamine- and methamphetamine-induced locomotor activity in the rat. Brain Res 2009, 1300:51-57.
16. Okuyama S., Chaki S., Kawashima N., Suzuki Y., Ogawa S., Kumagai T., et al. The atypical antipsychotic profile of NRA0045, a novel dopamine D4 and 5-hydroxytryptamine2A receptor antagonist, in rats. Br J Pharmacol 1997, 121:515-525.
17. Picard M., Morisset S., Cloix J.F., Bizot J.C., Guerin M., Beneteau V., et al. Pharmacological, neurochemical, and behavioural profile of JB-788, a new 5-HT1A agonist. Neuroscience 2010, 169:1337-1346.
18. Hirose A., Kato T., Ohno Y., Shimizu H., Tanaka H., Nakamura M., et al. Pharmacological actions of SM-9018, a new neuroleptic drug with both potent 5-hydroxytryptamine2 and dopamine2 antagonistic actions. Jpn J Pharmacol 1990, 53:321-329.
19. Bubar M.J., Pack K.M., Frankel P.S., Cunningham K.A. Effects of dopamine D1- or D2-like receptor antagonists on the hypermotive and discriminative stimulus effects of (+)-MDMA. Psychopharmacology 2004, 173:326-336.
20. Rudnick G., Wall S.C. The molecular mechanism of "ecstasy" [3,4-methylenedioxy-methamphetamine (MDMA)]: serotonin transporters are targets for MDMA-induced serotonin release. Proc Natl Acad Sci USA 1992, 89:1817-1821.
21. Callaway C.W., Johnson M.P., Gold L.H., Nichols D.E., Geyer M.A. Amphetamine derivatives induce locomotor hyperactivity by acting as indirect serotonin agonists. Psychopharmacology 1991, 104:293-301.
22. McCreary A.C., Bankson M.G., Cunningham K.A. Pharmacological studies of the acute and chronic effects of (+)-3,4-methylenedioxymethamphetamine on locomotor activity: role of 5-hydroxytryptamine1a and 5-hydroxytryptamine1b/1D receptors. J Pharmacol Exp Ther 1999, 290:965-973.
23. Müller C.P., Carey R.J., Huston J.P., De Souza Silva M.A. Serotonin and psychostimulant addiction: focus on 5-HTIA-receptors. Prog Neurobiol 2007, 81:133-178.
24. Adams J.U., Careri J.M., Efferen T.R., Rotrosen J. Differential effects of dopamine antagonists on locomotor activity, conditioned activity and conditioned place preference induced by cocaine in rats. Behav Pharmacol 2001, 12:603-611.
25. Auclair A., Blanc G., Glowinski J., Tassin J.P. Role of serotonin2A receptors in the D-amphetamine-induced release of dopamine: comparison with previous data on alpha1b-adrenergic receptors. J Neurochem 2004, 91:318-326.
26. Bankson M.G., Cunningham K.A. 3,4-Methylenedioxymethamphetamine (MDMA) as a unique model or serotonin receptor function and serotonin-dopamine interactions. J Pharmacol Exp Ther 2001, 297:846-852.
27. Filip M., Bubar M.J., Cunningham K.A. Contribution of serotonin (5-hydroxytryptamine; 5-HT) 5-HT2 receptor subtypes to the hyperlocomotor effects of cocaine: acute and chronic pharmacological analyses. J Pharmacol Exp Ther 2004, 310:1246-1254.
28. Filip M., Frankowska M., Zaniewska M., Golda A., Przegalinski E. The serotonergic system and its role in cocaine addiction. Pharmacol Rep 2005, 57:685-700.
29. Kita K., Shiratani T., Takenouchi K., Fukuzako H., Takigawa M. Effects of D1 and D2 dopamine receptor antagonists on cocaine-induced self-stimulation and locomotor activity in rats. Eur Neuropsychopharmacol 1999, 9:1-7.
30. McCreary A.C., Marsden C.A. Cocaine-induced behaviour: dopamine D1 receptor antagonism by SCH 23390 prevents expression of conditioned sensitisation following repeated administration of cocaine. Neuropharmacology 1993, 32:387-391.
31. McMahon L.R., Cunningham K.A. Antagonism of 5-hydroxytryptamine2a receptors attenuates the behavioural effects of cocaine in rats. J Pharmacol Exp Ther 2001, 297:357-363.
32. Fletcher P.J., Forster E.A., Bill D.J., Brown G., Cliffe I.A., Hartley J.E., et al. Electrophysiological, biochemical, neurohormonal and behavioural studies with WAY100635, a potent, selective and silent 5-HT1A receptor antagonist. Behav Brain Res 1996, 73:337-353.
33. Kehne J.H., Ketteler H.J., McCloskey T.C., Sullivan C.K., Dudley M.W., Schmidt C.J. Effects of the selective 5-HT2A receptor antagonist M100907 on MDMA-induced locomotor stimulation in rats. Neuropsychopharmacology 1996, 15:116-124.
34. Mosher T., Hayes D., Greenshaw A. Differential effects of 5-HT2C receptor ligands on place conditioning and locomotor activity in rats. Eur J Pharmacol 2005, 515:107-116.
35. Fletcher P.J., Grottick A.J., Higgin G.A. Differential effects of the 5HT2A receptor antagonist M100,907 and the 5HT2C receptor antagonist SB242,084 on cocaine-induced locomotor activity, cocaine self-administration and cocaine-induced reinstatement of responding. Neuropsychopharmacology 2002, 27:576-586.
36. Dunlop J., Sabb A.L., Mazandarani H., Zhang J., Kalgaonker S., Shukhina E., et al. WAY-163909 ((7bR,10aR)-1,2,3,4,8,9,10,10a-octahydro-7bH-cyclopenta-[b][1,4]diazepino[6,7,1hi]indole): a novel 5-HT2C receptor selective agonist with anorectic activity. J Pharmacol Exp Ther 2005, 313:862-869.
37. Grottick A.J., Fletcher P.J., Higgins G.A. Studies to investigate the role of 5-HT(2C) receptors on cocaine- and food-maintained behaviour. J Pharmacol Exp Ther 2000, 295:1183-1191.
38. Zocchi A., Fabbri D., Heidbreder C.A. Aripiprazole increases dopamine but not noradrenaline and serotonin levels in the mouse prefrontal cortex. Neurosci Lett 2005, 387:157-161.
39. Corbin A.E., Meltzer L.T., Ninteman F.W., Wiley J.N., Christoffersen C.L., Wustros D.J., et al. PD 158771, a potential antipsychotic agent with D2/D3 partial agonist and 5-HT1A agonist actions. II Preclinical behavioural effects. Neuropharmacology 2000, 39:1211-1221.
40. Gentry W.B., Ghafoor A.U., Wessinger W.D., Laurenzana E.M., Hendrickson H.P., Owens S.M. (+)-Methamphetamine-induced spontaneous behaviour in rats depends on route of (+)METH administration. Pharmacol Biochem Behav 2004, 79:751-760.
41. Zabik J.E., Levine R.M. Drug interactions with brain biogenic amines and the effects of amphetamine isomers on locomotor activity. Pharmacol Biochem Behav 1978, 8:429-435.
42. Segal D.S. Differential effects of para-chlorophenylalanine on amphetamine-induced locomotion and stereotypy. Brain Res 1976, 116:267-276.
43. Herges S., Taylor D.A. Modulatory effects of p-chlorophenylalanine microinjected into the dorsal and median raphe nuclei on cocaine-induced behaviour in the rat. Eur J Pharmacol 1999, 374:329-340.
44. Scheel-Kruger J., Braestrup C., Nielson M., Golembiowska K., Mogilnicka E. Cocaine: discussion on the role of dopamine in the biochemical mechanism of action. Cocaine and other stimulants 1977, 373-407. Plenum, New York. E.H. Ellinwood, M.M. Kilbey (Eds.).
45. Callaway C.W., Geyer M.A. Stimulant effects of 3,4-methylenedioxymethamphetamine in the nucleus accumbens of rat. Eur J Pharmacol 1992, 214:45-51.
46. Callaway C.W., Wing L.L., Geyer M.A. Serotonin release contributes to the locomotor stimulant effects of 3,4-methylenedioxymethamphetamine in rats. J Pharmacol Exp Ther 1990, 254:456-464.
47. Hilber B., Scholze P., Dorostka M.M., Sandtner W., Holy M., Boehm S., et al. Serotonin-transporter mediated efflux: a pharmacological analysis of amphetamines and non-amphetamines. Neuropharmacology 2005, 49:811-819.
48. Jordan S., Kramer G.L., Zukas P.K., Moeller M., Petty F. In vivo biogenic amine efflux in medial prefrontal cortex with imipramine, fluoxetine and fluvoxamine. Synapse 1994, 18:294-297.
49. Bubar M.J., McMahon L.R., De Deurwaerdere P., Spampinato U., Cunningham K.A. Selective serotonin uptake inhibitors enhance cocaine-induced locomotor activity and dopamine release in the nucleus accumbens. Neuropharmacology 2003, 44:342-353.
50. Sills T.L., Greenshaw A.J., Baker G.B., Fletcher P.J. Acute fluoxetine treatment potentiates amphetamine hyperactivity and amphetamine-induced nucleus accumbens dopamine release: possible pharmacokinetic interaction. Psychopharmacology (Berl) 1999, 141:421-427.
51. Nguyen E.C., McCracken K.A., Liu Y., Pouw B., Matsumoto R.R. Involvement of sigma (sigma) receptors in the acute actions of methamphetamine: receptor binding and behavioural studies. Neuropharmacology 2005, 49:638-645.
52. Kankaanpää A., Meririnne E., Seppälä T. 5-HT3 receptor antagonist MDL72222 attenuates cocaine- and mazindol-, but not methylphenidate-induced neurochemical and behavioural effects in the rat. Psychopharmacology (Berl) 2002, 159:341-350.
53. Battaglia G., De Souza E.B. Pharmacologic profile of amphetamine derivatives at various brain recognition sites: selective effects on serotonergic systems. NIDA Res Monogr 1989, 94:240-258.
54. Carey R.J., De Palma G., Damianopoulos E., Hopkins A., Shanahan A., Muller C.P., et al. Dopaminergic and serotonergic autoreceptor stimulation effects are equivalent and additive in the suppression of spontaneous and cocaine induced locomotor activity. Brain Res 2004, 1019:134-143.
55. Carey R.J., De Palma G., Damianopoulos E. Cocaine and serotonin: a role for the 5-HT(1A) receptor site in the mediation of cocaine stimulant effects. Behav Brain Res 2001, 126:127-133.
56. Müller C.P., Huston J.P. Determining the region-specific contributions of 5-HT receptors to the psychostimulant effects of cocaine. Trends Pharmacol Sci 2006, 27:105-112.
57. Przegalinski E., Filip M. Stimulation of 5-HT1A receptors attenuates the locomotor, but not the discriminative, effects of amphetamine and cocaine in rats. Behav Pharmacol 1997, 8:699-706.
58. De la Garza R., Cunningham K.A. The effects of 5-hydroxytryptamine(1A) agonist 8-hydroxy-2-(di-n-propulamino)tetralin on spontaneous activity, cocaine-induced behavioural sensitization: a microanalysis of locomotor activity. J Pharmacol Exp Ther 2000, 292:610-617.
59. Kehne J.H., Baron B.M., Carr A.A., Chaney S.F., Elands J., Feldman D.J., et al. Preclinical characterization of the potential of the putative atypical antipsychotic MDL100,907 as a potent 5-HT2A antagonist with a favourable CNS safety profile. J Pharmacol Exp Ther 1996, 277:968-981.
60. McMahon L.R., Filip M., Cunningham K.A. Differential regulation of the mesoaccumbens circuit by serotonin 5-hydroxytryptamine (5-HT)2A and 5-HT2C receptors. J Neurosci 2001, 21:7781-7787.
61. Fletcher P.J., Chintoh A.F., Sinyard J., Higgins G.A. Injection of the 5-HT2C receptor agonist Ro60-0175 into the ventral tegmental area reduces cocaine-induced locomotor activity and cocaine self-administration. Nueropsychopharmacology 2004, 29:308-318.
62. Steffenson S.C., Svingos A.L., Pickel V.M., Henrikson S.J. Electrophysiological characterization of GABAergic neurons in the ventral tegmental area. J Neurosci 1998, 18:8003-8015.
63. Shank E.J., Seitz P.K., Bubar M.J., Stutz S.J., Cunningham K.A. Selective ablation of GABA neurons in the ventral tegmental area increases spontaneous locomotor activity. Behav Neurosci 2007, 121:1224-1233.
64. Bubar M.J., Cunningham K.A. Distribution of serotonin 5-HT2C receptors in the ventral tegmental area. Neuroscience 2007, 146:286-297.
65. Yamamoto B.K., Nash J.F., Gudelsky G.A. Modulation of methylenedioxymethamphetamine-induced striatal dopamine release by the interaction between serotonin and gamma-aminobutyric acid in the substantia nigra. J Pharmacol Exp Ther 1995, 273:1063-1070.
66. Gudelsky G.A., Nash J.F. Carrier-mediated release of serotonin by 3, 4-methylenedioxymethamphetamine: implications for serotonin-dopamine interactions. J Neurochem 1996, 66:243-249.
67. Doherty M.D., Pickel V.M. Ultrasonic localization of the serotonin 2A receptor in dopaminergic neurons in the ventral tegmental area. Brain Res 2000, 864:176-185.
68. Erhardt S., Mathe J.M., Cherqui K., Engberg G., Svensson T.H. GABA(B) receptor-mediated modulation of the firing pattern of ventral tegmental area dopamine neurons in vivo. Naunyn Schmiedebergs Arch Pharmacol 2002, 365:173-180.
69. Filip M., Alenina N., Bader M., Przegalinski E. Behavioural evidence for the significance of serotonergic (5-HT) receptors in cocaine addiction. Addict Biol 2010, 15:227-249.
70. Przegalinski E., Filip M., Papla I., Czepiel K. Effects of 5-HT1B receptor ligands microinjected into accumbal shell or core on the cocaine-induced locomotor hyperactivity in rats. J Physiol Pharmacol 2002, 53:383-394.
71. McCreary A.C., Callahan P.M., Cunningham K.A. The locomotor stimulant and discriminative stimulus effects of cocaine: Assessment of the 5-HT1B/1D antagonist GR127935. NIDA Res Monogr 1997, 178:301.
72. Chaouloff F., Courvoisier H., Moisan M.P., Mormede P. GR 127935 reduces basal locomotor activity and prevents RU-24969-, but not amphetamine-induced hyperlocomotion, in the Wistar-Kyoto Hyperactive (WKHA) rat. Psychopharmacology 1999, 141:326-331.
73. Iyer R.N., Bradberry C.W. Serotonin-mediated increase in prefrontal cortex dopamine release: pharmacological characterization. J Pharmacol Exp Ther 1996, 277:40-47.
74. Parsons L.H., Koob G.F., Weiss F. RU 24969, a 5-HT1B/1A receptor agonist, potentiates cocaine-induced increases in nucleus accumbens dopamine. Synapse 1999, 32:132-135.
75. Ng N.K., Lee H.S., Wong P.T. Regulation of striatal dopamine release through 5-HT1 and 5-HT2 receptors. J Neurosci Res 1999, 55:600-607.
76. Filip M., Papla I., Nowak E., Przegalinski E. Blocking impact of clozapine on cocaine locomotor and sensitizing effects in rats. Pol J Pharmacol 2003, 55:1125-1130.
77. Cahir M., King D.J. Antipsychotics lack α1A/B adrenoreceptor subtype selectivity in the rat. Eur Neuropsychopharmacol 2005, 15:231-234.
78. Johnson D.E., Nedza F.M., Spracklin D.K., Ward K.M., Schmidt A.W., Iredale P.A., et al. The role of muscarinic receptor antagonism in antipsychotic-induced hippocampal acetylcholine release. Eur J Pharmacol 2005, 506:209-219.
79. Schweiler L., Engberg G., Erhardt S. Clozapine modulates midbrain dopamine neuron firing via interaction with the NMDA receptor complex. Synapse 2004, 52:114-122.
80. Brunello N., Masotto C., Steardo L., Markstein R., Racagni G. New insights into the biology of schizophrenia through the mechanism of action of clozapine. Neuropsychopharmacology 1995, 13:177-213.
81. Jordan S., Koprivica V., Chen R., Tottori K., Kikuchi T., Altar C.A. The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor. Eur J Pharmacol 2002, 441:137-140.
82. Meltzer H.Y. The role of serotonin in antipsychotic drug action. Neuropsychopharmacology 1999, 21:106-115.
83. Schmidt C.J., Sorensen S.M., Kehne J.H., Carr A.A., Palfreyman M.G. The role of 5-HT2A receptors in antipsychotic activity. Life Sci 1995, 56:2209-2222.
84. Newman-Tancredi A., Assie M.B., Leduc N., Ormiere A.M., Danty N., Cosi C. Novel antipsychotics activate recombinant human and native rat serotonin 5-HT1A receptors: affinity, efficacy and potential implications for treatment of schizophrenia. Int J Neuropsychopharmacol 2005, 8:341-356.
85. Schmidt C.J., Ritter J.K., Sonsalla P.K., Hanson G.R., Gibb J.W. Role of dopamine in the neurotoxic effects of methamphetamine. J Pharmacol Exp Ther 1985, 233:539-544.